AI Prognosis: A 2023 health AI bet that seems to be paying off
You’re reading the web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guide to artificial intelligence in health…
GOP Sen. Johnson investigating FDA rare disease drug rejections
WASHINGTON — Sen. Ron Johnson (R-Wis.) said he is investigating the Food and Drug Administration’s rejections of rare disease…
How Hims has transformed medicine in a few short years
As the Super Bowl approached halftime, Hims & Hers publicly staked its claim to preventive medicine in front…
Health tech company says it will join Medicare’s new chronic care experiment
Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics.…
Science Corp. raises $230 million as it awaits FDA decision
O. Rose Broderick reports on the health policies and technologies that govern people with disabilities’ lives. Before coming…
UnitedHealth’s massive growth just got harder to track
Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences…
FDA offers clues to AI regulation with RecovryAI designation
Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the…
Why clinical trials on nutritional supplements are hard to design
Walk into any drugstore, natural market, or Costco and you’ll find a dazzling array of supplements promising everything…
Digital twins in health care: Promising technology still years away
Two decades ago, futurist Ray Kurzweil laid out a bold vision for next-generation medicine in his book “The…
FDA taps AI executive to lead digital health center
Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics.…
FDA’s Høeg plans to scrutinize SSRIs, RSV shots for babies
WASHINGTON — Tracy Beth Høeg, the top drug regulator at the Food and Drug Administration, indicated in her…
We’re reading about China’s GLP-1 drugs, a puzzling FDA rejection
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and rewarding…